Opendata, web and dolomites
H2020 projects about "inhibitor"
The page lists 87 projects related to the topic "inhibitor".
| # | |||
|---|---|---|---|
| 1 | MoTriColor | Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor) | 2015 |
| 2 | QUANTPATTERN | Quantitative analysis of Nodal/Lefty-mediated pattern formation | 2015 |
| 3 | DE-ORPHAN | DEtermination of Orphan Receptor PHysiological Agonists and sigNals | 2015 |
| 4 | ButaNexT | Next Generation Bio-butanol | 2015 |
| 5 | CannaPreg | Development of pregnenolone derivatives as allosteric inhibitors of CB1 cannabinoid receptors for the treatment of schizophrenia and psychotic syndromes | 2015 |
| 6 | MHAtriCell | Hyaluronan-rich matrices crosslinked with collagen-like peptides for 3D culture of ovarian cancer cells | 2015 |
| 7 | ID4 | Role of Id4 in the adult subventricular zone of normal and injured brain | 2015 |
| 8 | TITLY | Inhibition of the T-cell receptor signalling pathway for treatment of T-cell lymphoma | 2015 |
| 9 | HepatoRiSK | A new tumor suppressor role for RSK2 in hepatocellular carcinoma | 2015 |
| 10 | SUMOblock | Blocking SUMO conjugation as drug discovery strategy. | 2015 |
| 11 | WONDANTS | Wonder Ants — A new eco-friendly-innovation solution to persistent invasive ants. | 2015 |
| 12 | Phd | Deciphering PI3K biology in health and disease | 2015 |
| 13 | NutrientSensingVivo | The Physiology of Nutrient Sensing by mTOR | 2016 |
| 14 | BIOVALID | Clinical validation of the DiviTum assay in two high profile clinical studies in Europe | 2015 |
| 15 | ALBINO | Effect of ALlopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome | 2016 |
| 16 | LeukoPredict | LeukoPredict: an in vitro system predicting and monitoring the therapeutic response of patients in the cure of Chronic Myeloid Leukemia (CML). | 2016 |
| 17 | CODIC | COmmercializing first-in-class dCTPase Inhibitors for treatment of hematological Cancers | 2016 |
| 18 | SWEETOOLS | Smart Biologics: Developing New Tools in Glycobiology | 2016 |
| 19 | PEPTO1 | Feasibility study of a novel treatment for cancer based on a recombinant peptide therapy | 2016 |
| 20 | PURKINJEREG | Identification of cellular identities and characterization of the STAT3 signalling pathway in Purkinje cell layer regeneration | 2016 |
| 21 | Wnt and CRC | Therapeutic inhibition of the oncogenic Wnt/beta-catenin pathway in mismatch repair deficient hypermutant tumors | 2017 |
| 22 | 2MoveMate4Melanoma | A treatment for BRAF inhibitor resistant melanoma | 2016 |
| 23 | LightningPro | Lightning inhibition for protection of urban soft targets and critical infrastructure against lightning strikes. | 2016 |
| 24 | GBM-CPP | Developing an anti-Myc cell-penetrating peptide for cancer treatment | 2016 |
| 25 | AngioResist | Coordinated Development of Inhibitors and Biomarkers for Resistance to Antiangiogenics in Cancer - AngioResist | 2016 |
| 26 | LSDiASD | Leveraging Small Demethylase inhibitors for Autism Spectrum Disorder | 2016 |
| 27 | PFKFBLOCK | Translating fundamental insights in endothelial metabolism: PFKFB3 drug discovery and development | 2016 |
| 28 | EPITOR | NEUROBIOLOGY OF EPILEPSY GENES | 2016 |
| 29 | SWEETBULLETS | Sweet Theranostics in Bitter Infections - Seek and Destroy | 2017 |
| 30 | CD40-INN | CD40 goes innate: defining and targeting CD40 signaling intermediates in the macrophage to treat atherosclerosis | 2016 |
| 31 | HYPOXIMMUNO | Tackling the Achilles Heel of Immunotherapy: Validating imaging biomarkers and targeting the immunological niche of tumour hypoxia | 2016 |
| 32 | TKI resistance | Resistance mechanisms to tyrosine kinase inhibitors in solid tumors | 2016 |
| 33 | LungCARD | Blood test for clinical therapy guidance of non-small cell lung cancer patients | 2017 |
| 34 | Schizo-EPICOG | Inflammatory processes underlying cognitive deficits in schizophrenia: epigenetic mechanisms and pharmacological regulation | 2018 |
| 35 | TSPO METALLODRUGS | Novel, highly effective and selective anticancer metallodrugs | 2018 |
| 36 | CRISTONE | Targeting CRISPR-based HDAC inhibitors to histones: a new tool for assessing mechanisms of class I HDAC inhibitors and developing chemical probes. | 2017 |
| 37 | TRIBBLES | Characterizing the clinical relevance and the mechanism underlying TRIB2-mediated drug resistance to MEK inhibitiors in the context of melanoma | 2018 |
| 38 | DualFun | Dual Function Polymer Materials for Blood Contacting Applications | 2017 |
| 39 | PCAGED-KI | Photocaged Kinase Inhibitors as Molecular Tools for Investigating Neurodegenerative Diseases | 2017 |
| 40 | LIsTEN | β-Lactams as flaviviral NS3 protease inhibitors | 2017 |
| 41 | ONCOPHAGY | Novel Atg4B-inhibitors and dual [Atg4B-carbonic anhydrase]inhibitors for interfering with cytoprotective mechanisms of cancercells in the acidic tumor micro-environment. | 2017 |
| 42 | NEUROMODEL | Statistical Modelling for relating multimodal neuroimaging to clinical outcomes in order to predict patient response to depression therapy. | 2017 |
| 43 | ALMAGIC | Aluminium and Magnesium Alloys Green Innovative Coatings | 2017 |
| 44 | DynaCOMP | Assessing compounds targeting DNA replication licensing complexes as anti-tumor agents | 2017 |
| 45 | TRIPLECON | Triple negative breast cancer control through synergistic inhibition of EGFR and CDK9 signaling | 2017 |
| 46 | ANTIViR | Molecular mechanisms of interferon-induced antiviral restriction and signalling | 2017 |
| 47 | OMVCRC | Engineered bacterial Outer Membrane Vesicles (OMVs) for colorectal cancer immunotherapy | 2018 |
| 48 | CC-LEGO | CC-LEGO: robust protein blocks to build cages and layers | 2018 |
| 49 | EMBRACE | Elucidating Mechanisms of Bladder Cancer Metastasis | 2018 |
| 50 | Za-AV | Determination of physiologically relevant RNA substrate(s) and design of small-molecule inhibitors for Zα domains as potential intervention strategies for viral infections and autoimmunity | 2018 |
| 51 | Proteasome in cancer | Identification of the proteasome machinery targets in human cancer | 2018 |
| 52 | Entero3D | In situ 3D structures of viral replication complexes: cryo-electron tomography of enterovirus-infected cells | 2019 |
| 53 | ProCenDecl | Synthesis and validation of chemical Probes for Centrosome Declustering: development of potent and selective anti-cancer agents. | 2019 |
| 54 | HDAC6_GEMM | Development of a novel genetically engineered mouse model to study the role of HDAC6 in oncogenesis and metastasis of non-small cell lung cancer. | 2018 |
| 55 | POLICE | The PIDDosome in Centrosome and Ploidy-Surveillance | 2018 |
| 56 | Cr VI FREE COATING | Development of an innovative alternative to the use of hexavalent chromium in the aerospace coating | 2018 |
| 57 | SYST-iMYC | Development of an effective and safe systemic Myc inhibitor for the treatment of multiple cancer types. | 2018 |
| 58 | CL-IO | Commercial feasibility of non-pathogenic Clostridium-Mediated Cancer Immunotherapy: leveraging the presence of tumour hypoxia & necrosis | 2018 |
| 59 | EPI-X4Health | Therapeutic potential of optimized derivatives of an endogenous CXCR4 antagonist for the treatment of cancers and inflammatory diseases | 2018 |
| 60 | NextGen IO | Exploiting the hypoxia response in T cells for Next-Generation Immuno-Oncology | 2019 |
| 61 | PanCaVax | Personalised Pancreatic Cancer Vaccination Therapy derived from Autologous Tumor Cells and Neoantigens | 2018 |
| 62 | CONQR | Translation and Commercialization of a QSOX1-inhibitory Antibody Targeting the Tumor Microenvironment in Breast Cancer | 2018 |
| 63 | inCITe | Seeing Citrulline: A Molecular Toolbox for Peptidyl Arginine Deiminases | 2019 |
| 64 | AutoCAb | Automated computational design of site-targeted repertoires of camelid antibodies | 2019 |
| 65 | Capsulight | The first ingestible capsule for eradicating Helicobacter pylori infection through photodynamic therapy | 2019 |
| 66 | CaLA | The Capillary Lock Actuator: A novel bistable microfluidic actuator for cost-effective high-density actuator arrays suitable for large-scale graphical tactile displays | 2019 |
| 67 | EV-2C | Structural and functional studies of enterovirus 2C proteins: promising targets for antiviral therapy. | 2019 |
| 68 | SSHelectPhagy | Regulation of Selective autophagy by sulfide through persulfidation of protein targets. | 2019 |
| 69 | iRhomADAM | Uncovering the role of the iRhom2-ADAM17 interaction in inflammatory signalling | 2020 |
| 70 | IA-NANO | Albumin particles for intra-articular delivery of celecoxib to treat osteoarthritic inflammation. | 2019 |
| 71 | IDEAL | Inhibitor of DUX4-IGH to Erase Acute lymphoblastic Leukaemia | 2020 |
| 72 | MINT | Multifunctional Immunocompatible NanoTheranostics to modulate tumor microenvironment and improve treatment monitoring: A double blow to pancreatic cancer | 2019 |
| 73 | STOPFOP | Saracatinib Trial tO Prevent FOP | 2019 |
| 74 | TENDO | Tension of ENDOmembranes maintained by TORC1 | 2019 |
| 75 | MIMIC | Mapping and modulating integrin mediated interactions | 2020 |
| 76 | FEN INHIBITORS | Development of Kinetoplastida Flap Endonuclease Inhibitors in Search for Novel Therapeutics | 2020 |
| 77 | MYCure | Innovative cancer therapy through Myc inhibition: taking OMO-103 to market | 2019 |
| 78 | TaMIE | Targeting MarA to Inhibit Efflux | 2019 |
| 79 | PROT-RESIST | Toward the Commercialization of a Proteolytically Resistant APPI Variant for Inhibiting Metastasis in Prostate and Pancreatic Cancer | 2019 |
| 80 | Hydroptics | Photonics sensing platform for process optimisation in the oil industry | 2019 |
| 81 | EcoFoil | Innovative, sustainable and globally unique storage method for food preservation | 2019 |
| 82 | EDUC8 | Early Stage Researchers EDUCational Program on Factor VIII Immunogenicity | 2020 |
| 83 | Meta-Targeting | Macro-Nanomedicine to Treat Metastatic Cancer | 2020 |
| 84 | inhibiTOR | Novel selective mTORC1 inhibitors | 2020 |
| 85 | REpAIR | Spatio-Temporal Regulation of Inflammation and Tissue Regeneration: Studying the immune system - tissue - microbiota communication to develop targeted therapies for immune-mediated diseases and cancer | 2020 |
| 86 | BESG | Bioengineered exosomes based approaches for the effective treatment of non-small cell lung cancer | 2020 |
| 87 | DREAM | Dux4-Regulated Expression and Activity by MATR3 | 2020 |